Callan Family Office’s Gilead Sciences GILD Stock Holding History

Callan Family Office’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.8M	Sell	101,450 -2,321	-2%	-$306K	0.25%	79
2026 Q1	$14.5M	Sell	103,771 -2,099	-2%	-$294K	0.33%	60
2025 Q4	$13M	Buy	105,870 +17,592	+20%	+$2.14M	0.28%	69
2025 Q3	$9.8M	Sell	88,278 -1,460	-2%	-$166K	0.31%	62
2025 Q2	$9.95M	Buy	89,738 +63,300	+239%	+$6.74M	0.31%	60
2025 Q1	$2.96M	Sell	26,438 -4,149	-14%	-$428K	0.22%	100
2024 Q4	$2.83M	Buy	+30,587	New	+$2.75M	0.18%	113
2023 Q2	–	Sell	-13,778	Closed	-$1.14M	–	131
2023 Q1	$1.14M	Buy	+13,778	New	+$1.14M	0.28%	54

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Callan Family Office's GILD Position: Q2 2026 in Review

Callan Family Office reduced its Gilead Sciences (GILD) stake by 2.2% in Q2 2026, selling an estimated $306K and leaving 101,450 shares worth $12.8M. The position accounts for 0.25% of the portfolio, ranked #79.

Callan Family Office first reported a position in GILD in Q1 2023 and has held it in 8 quarters since. The position peaked at $14.5M in Q1 2026. 2,293 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Callan Family Office held 101,450 shares of Gilead Sciences worth $12.8M as of Q2 2026.
Callan Family Office sold 2,321 Gilead Sciences shares in Q2 2026, an estimated $306K.
Gilead Sciences made up 0.25% of Callan Family Office's portfolio in Q2 2026, its #79 holding.
Callan Family Office first reported a position in Gilead Sciences in Q1 2023 and has held it in 8 quarters since.
Callan Family Office's Gilead Sciences position peaked at $14.5M in Q1 2026.
2,293 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.